Database : HANSEN Search on : ANTIINFECCIOSOS [Subject descriptor] References found : 29 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 2

go to page

1 / 29

HANSEN

select to print

Id: 17691 Author: Scollard, D. M; Adams, L. B; Gillis, T. P; Krahenbuhl, J. L; Truman, R. W; Williams, D. L Title: The continuing challenges of leprosy ..- Source: s.l; s.n; 2006. 44 p. ilus, tab. Abstract: Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases. (AU). Descriptors: Antiinfecciosos/TU Proteínas de Bactérias/ME Vacinas Bacterianas Modelos Animais de Doenças Suscetibilidade à Doença/IM Resistência Bacteriana a Drogas Genes Bacterianos/GE Predisposição Genética para Doença Genoma Bacteriano Imunidade Celular Imunidade Natural/GE Hansenostáticos/PD/TU Hanseníase/*/DI/MI/TH Mycobacterium leprae/*/CH/DE/IP/PH Nervos Periféricos/MI Doenças do Sistema Nervoso Periférico/MI/PA Reação em Cadeia da Polimerase Research Support, N.I.H., Extramural Células de Schwann/IM/MI Limits: HUMANO ANIMAL CAMUNDONGOS SUPPORT, NON-U.S. GOV'T Location: BR191.1; 09365/S

2 / 29

HANSEN

select to print

Id: 17310 Author: Grimald, J; Vallat, J. M Title: Manifestations neurologiques de la lepre Neurological manifestations of leprosy- Source: s.l; s.n; 2003. 19 p. . Abstract: Leprosy, also known as Hansen's disease, is a chronic, infectious disease caused by Mycobacterium leprae. Bacilli localize preferentially in the skin and peripheral nerves and have a propensity to cause nerve damage. The resulting disability has caused great suffering for victims in many countries. Despite recent advances in the immunopathogenesis, epidemiology and prognostic factors of leprosy nerve damage, many aspects of the disease have remained enigmatic. The spectrum of clinical and pathological manifestations of the disease ranges from lepromatous to tuberculoid, depending on the host's T-cell-mediated immune response. Diagnosis is based on three criteria: characteristic skin lesions in association with thickened nerves, demonstration of acid fast bacilli in slit skin smears, and histopathology of skin biopsies. Nerve biopsy is necessary to establish the diagnosis of pure "neural leprosy". In developed countries, the diagnosis is suspected when a patient who has stayed in an endemic area suffers from a peripheral neuropathy of unknown etiology. To facilitate determination of the appropriate antibiotic regimen, patients are classified as either paucibacillary or multibacillary. Some patients may have multibacillary leprosy in nerves and paucibacillary leprosy in skin, which emphasizes the usefulness of nerve biopsy. The course of the disease is often complicated by immune mediated "reactions", which can rapidly lead to further nerve damage, namely reversal reaction and erythema nodosum leprosy. However, nerves are often functionally impaired before developing obvious symptoms such as skin reactions or nevralgia (silent neuropathy). Early recognition and prompt treatment with corticosteroids of leprous reactions and "silent neuropathies" is very important to prevent disability with all its attendant problems. Research progress from clinical trials may improve current methods of prevention and treatment of nerve damage in leprosy.(AU). Descriptors: Antiinfecciosos/TU Biópsia Diagnóstico Diferencial Hanseníase/DT/*PA/VI Mycobacterium leprae/IP Nervos Periféricos/*PA/VI Pele/VI Limits: Humano Location: BR191.1; 00254/s

3 / 29

HANSEN

select to print

Id: 15629 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CELULAS CULTIVADAS CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox MACROFAGOS/ef drogas TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

4 / 29

HANSEN

select to print

Id: 13945 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox CELULAS CULTIVADAS MACROFAGOS/ef drogas MACROFAGOS/microbiol TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO/quim Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

5 / 29

HANSEN

select to print

Id: 13330 Author: Tarabini-Castellani, Giovanni Title: El Bactrim en el mal perforante plantar hanseniano ..- Source: s.l; s.n; July-Dec. 1971. 22 p. . Abstract: As a first step, two groups of 34 leprosy patients with perforating ulcers were included in this...(AU). Descriptors: ESTUDOS DE AVALIACAO ANTIINFECCIOSOS/uso terap ANTAGONISTAS DO ACIDO FOLICO/uso terap DOENCAS DO PE/quimioter HANSENIASE/quimioter TRIMETOPRIM/uso terap ULCERA/quimioter - PENICILINAS/uso terap  PIRIMIDINAS/uso terap  SULFAMETOXAZOL/uso terap  TETRACICLINA/uso terap Limits: ESTUDO COMPARATIVO ADOLESCENTE Electronic Medium: http://www.ilsl.br Location: BR191.1; 01220/s

6 / 29

HANSEN

select to print

Id: 12238 Author: Maeda, Shinji; Matsuoka, Masanori; Nakata, Noboru; Kai, Masanori; Maeda, Yumi; Hashimoto, Ken; Kimura, Hiroaki; Kobayashi, Kazuo; Kashiwabara, Yoshiko Title: Multidrug resistant mycobacterium leprae from patients with leprosy ..- Source: s.l; s.n; Dec. 2001. 5 p. tab, graf. Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIBIOTICOS ANTITUBERCULOSE ANTIBIOTICOS ANTITUBERCULOSE SEQUENCIA DE BASES PRIMERS DO DNA DNA BACTERIANO DNA BACTERIANO RESISTENCIA MICROBIANA A DROGAS RESISTENCIA A MULTIPLAS DROGAS GENES BACTERIANOS GENES BACTERIANOS LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE CAMUNDONGOS DADOS DE SEQUENCIA MOLECULAR MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE OFLOXACINA OFLOXACINA RIFAMPINA RIFAMPINA REACAO EM CADEIA POR POLIMERASE VIA TRANSCRIPTASE REVERSA Limits: ANIMAL Location: BR191.1; 08640/s

7 / 29

HANSEN

select to print

Id: 12122 Author: Ochoa, Maria Teresa; Stenger, Steffer; Sieling, Peter A; Thoma-Uszynski, Sybille; Sabet, Shereen; Cho, Sungae; Krensky, Alan M; Rollinghoff, Martin; Sarno, Euzenir Nunes; Burdick, Anne E; Rea, Thomas H; Modlin, Robert L Title: T-cell release of granulysin contributes to host defense in leprosy ..- Source: s.l; s.n; feb. 2001. 6 p. ilus, graf. Descriptors: ANTIINFECCIOSOS ANTIGENOS CD3 ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T LINFOCITOS T CD4-POSITIVOS HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA HANSENIASE TUBERCULOIDE HANSENIASE TUBERCULOIDE Células Cultivadas Location: BR191.1; 08698/s

8 / 29

HANSEN

select to print

Id: 11935 Author: Cohen, Jack B Title: Cutaneous involvement of dermatomyositis can respond to dapsone therapy ..- Source: s.l; s.n; 2002. 3 p. . Descriptors: DERMATOMIOSITE DERMATOMIOSITE ANTIINFECCIOSOS DAPSONA DIAGNOSTICO DIFERENCIAL HIDROXICLOROQUINA IMUNOSSUPRESSORES PREDNISONA QUINACRINA Location: BR191.1; 08596/s

9 / 29

HANSEN

select to print

Id: 11727 Author: Sehgal, Virendra N; Kumar, Sunil; Jain, Sanjiv; Bhattacharya, Samit N Title: Relapse (reactivation) in borderline tuberculoid (BT) leprosy ..- Source: s.l; s.n; 1998. 2 p. ilus. Descriptors: HANSENIASE DIMORFA HANSENIASE DIMORFA HANSENIASE TUBERCULOIDE HANSENIASE TUBERCULOIDE LEPROSTATICOS AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIBIOTICOS TETRACICLINICOS DAPSONA GRANULOMA HISTIOCITOS LINFOCITOS MINOCICLINA RECIDIVA RIFAMPINA Limits: ADULTO HUMANO MASCULINO Location: BR191.1; 07324/s

10 / 29

HANSEN

select to print

Id: 11685 Author: Ochoa, Maria-Teresa; Stenger, Steffen; Sieling, Peter A; Thoma-Uszynski, Sybille; Sabet, Shereen; Cho, Sungae; Krensky, Alan M; Rollinghoff, Martin; Sarno, Euzenir Nunes; Burdick, Anne E; Rea, Thomas H; Modlin, Robert L Title: T-cell release of granulysin contributes to host defense in leprosy ..- Source: s.l; s.n; 2001. 6 p. ilus, graf. Descriptors: HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA HANSENIASE TUBERCULOIDE HANSENIASE TUBERCULOIDE ANTIINFECCIOSOS ANTIGENOS CD3 ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T LINFOCITOS T CD4-POSITIVOS Location: BR191.1; 08477/s

11 / 29

HANSEN

select to print

Id: 11683 Author: Paniker, Uma; Levine, Norman Title: Dapsone and sulfapyridine ..- Source: s.l; s.n; 2001. 8 p. ilus, tab. Descriptors: HANSENIASE DERMATOPATIAS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES DAPSONA DAPSONA DAPSONA DAPSONA AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS SULFAPIRIDINA SULFAPIRIDINA SULFAPIRIDINA SULFAPIRIDINA Location: BR191.1; 08475/s

12 / 29

HANSEN

select to print

Id: 11643 Author: Cohen, Jack B Title: Cutaneous involvement of dermatomyositis can respond to dapsone therapy ..- Source: s.l; s.n; 2002. 3 p. . Descriptors: DERMATOMIOSITE DERMATOMIOSITE ANTIINFECCIOSOS DAPSONA DIAGNOSTICO DIFERENCIAL HIDROXICLOROQUINA IMUNOSSUPRESSORES PREDNISONA QUINACRINA Location: BR191.1; 08504/s

13 / 29

HANSEN

select to print

Id: 11445 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, monofloxacin, and rifapentine against mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIBIOTICOS MACROLIDIOS ANTIBIOTICOS MACROLIDIOS PÉ LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE CAMUNDONGOS TESTES DE SENSIBILIDADE MICROBIANA MYCOBACTERIUM LEPRAE RIFAMPINA RIFAMPINA RIFAMPINA Limits: ESTUDO COMPARATIVO ANIMAL Location: BR191.1; 08327/s

14 / 29

HANSEN

select to print

Id: 11313 Author: John, Deepa; Daniel, Ebenezer Title: Infectious keratitis in leprosy ..- Source: s.l; s.n; 1999. 4 p. tab. Descriptors: ANTIINFECCIOSOS CIPROFLOXACINA ULCERA DA CORNEA ULCERA DA CORNEA KETOCONAZOL HANSENIASE LEPROMATOSA HANSENIASE TUBERCULOIDE FATORES DE RISCO ACUIDADE VISUAL Location: BR191.1; 07252/s

15 / 29

HANSEN

select to print

Id: 11311 Author: Villahermosa, Laarni G; Walsh, Douglas S; Fajardo Junior, Tranquilino T; Abalos, Rodolfo M; dela Cruz, Eduardo C; Veerasubramanian, Priya; Walsh, Gerald P Title: Resolution of lepromatous leprosy after a short course of amoxicillin / clavulanic acid, followed by ofloxacin and clofazimine ..- Source: s.l; s.n; 1999. 3 p. ilus. Descriptors: AMOXICILINA ANTIINFECCIOSOS ACIDOS CLAVULANICOS CLOFAZIMINA QUIMIOTERAPIA COMBINADA HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE OFLOXACINA PELE PELE RESULTADO DE TRATAMENTO Location: BR191.1; 07250/s

16 / 29

HANSEN

select to print

Id: 11024 Author: Zoprbas, P; Kontochristopoulos, G; Detsi, I; Apostolakis, E; Kouris, N; Katsambas, A Title: Borderline tuberculoid leprosy coexisting with systemic lupus erythematosus ..- Source: s.l; s.n; may 1999. 2 p. . Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIINFLAMATORIOS ESTEROIDES CIPROFLOXACINA ULCERA DO PÉ ULCERA DO PÉ HANSENIASE DIMORFA HANSENIASE DIMORFA HANSENIASE DIMORFA LUPUS ERITEMATOSO SISTEMICO LUPUS ERITEMATOSO SISTEMICO LUPUS ERITEMATOSO SISTEMICO PREDNISOLONA Limits: RELATO DE CASO Location: BR191.1; 07489/s

17 / 29

HANSEN

select to print

Id: 10251 Author: Bermudez, Luiz E Title: Use of liposome preparation to treat mycobacterial infections ..- Source: s.l; s.n; 1994. 6 p. . Descriptors: INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS ANTIINFECCIOSOS ANTITUBERCULOSOS PORTADORES DE DROGAS HANSENIASE LIPOSSOMOS MICOBACTERIOSE MICOBACTERIOSE INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE TUBERCULOSE TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS Location: BR191.1; 06961/s

18 / 29

HANSEN

select to print

Id: 10212 Author: Chan, Gertrude P; Garcia-Ignacio, Bernadette Y; Chavez, Virginia E; Livelo, Jocelyn B; Jimenez, Claribel L; Parrilla, Manuela Luisa R; Franzblau, Scott G Title: Clinical trial of sparfloxacin for lepromatous leprosy ..- Source: s.l; s.n; 1994. 5 p. tab. Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIGENOS DE BACTÉRIAS PÉ GLICOLIPIDIOS HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA CAMUNDONGOS MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE OXIRREDUÇAO ACIDOS PALMITICOS QUINOLONAS ESPIROMETRIA Location: BR191.1; 06913/s

19 / 29

HANSEN

select to print

Id: 10167 Author: Bermudez, Luiz E Title: Use of liposome preparation to treat mycobacterial infections ..- Source: s.l; s.n; 1994. 6 p. . Descriptors: HANSENIASE INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS ANTIINFECCIOSOS ANTITUBERCULOSOS PORTADORES DE DROGAS LIPOSSOMOS MICOBACTERIOSE INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE TUBERCULOSE TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS Location: BR191.1; 07080/s

20 / 29

HANSEN

select to print

Id: 10140 Author: Cambau, Emmanuelle; Perani, Evelyne; Guillemin, Isabelle; Jamet, Pierre; Ji, Baohong Title: Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae ..- Source: s.l; s.n; 1997. 2 p. tab. Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA DAPSONA RESISTENCIA A MULTIPLAS DROGAS QUIMIOTERAPIA COMBINADA LEPROSTATICOS HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE OFLOXACINA RIFAMPINA Limits: RELATO DE CASO Location: BR191.1; 07114/s

---

page 1 de 2

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information